MX2020005765A - Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. - Google Patents

Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.

Info

Publication number
MX2020005765A
MX2020005765A MX2020005765A MX2020005765A MX2020005765A MX 2020005765 A MX2020005765 A MX 2020005765A MX 2020005765 A MX2020005765 A MX 2020005765A MX 2020005765 A MX2020005765 A MX 2020005765A MX 2020005765 A MX2020005765 A MX 2020005765A
Authority
MX
Mexico
Prior art keywords
mutated ras
restricted
hla class
cell receptors
tcr
Prior art date
Application number
MX2020005765A
Other languages
English (en)
Inventor
Steven A Rosenberg
Gal Cafri
Yong- Chen LU
Rami Yoseph
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2020005765A publication Critical patent/MX2020005765A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses

Abstract

Se describe un receptor de células T aisladas o purificadas (TCR), en donde el TCR tiene especificidad antigénica para una secuencia de aminoácidos de RAS mutado presentado por una molécula de antígeno leucocitario humano (HLA) clase I. También se proporcionan polipéptidos y proteínas relacionadas, así como ácidos nucleicos relacionados, vectores de expresión recombinante, células hospedadoras, poblaciones de células, y composiciones farmacéuticas. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos para tratar o prevenir el cáncer en un mamífero.
MX2020005765A 2017-12-04 2018-12-03 Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. MX2020005765A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762594244P 2017-12-04 2017-12-04
PCT/US2018/063581 WO2019112941A1 (en) 2017-12-04 2018-12-03 Hla class i-restricted t cell receptors against mutated ras

Publications (1)

Publication Number Publication Date
MX2020005765A true MX2020005765A (es) 2020-09-25

Family

ID=64949411

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005765A MX2020005765A (es) 2017-12-04 2018-12-03 Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.

Country Status (15)

Country Link
US (2) US11466071B2 (es)
EP (1) EP3720478A1 (es)
JP (2) JP7385566B2 (es)
KR (1) KR20200115484A (es)
CN (1) CN111836638A (es)
AU (1) AU2018378200A1 (es)
BR (1) BR112020011111A2 (es)
CA (1) CA3084246A1 (es)
CR (1) CR20200287A (es)
EA (1) EA202091335A1 (es)
IL (1) IL275031A (es)
MA (2) MA51042A (es)
MX (1) MX2020005765A (es)
SG (1) SG11202005236QA (es)
WO (1) WO2019112941A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063905A1 (en) * 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
US20220088190A1 (en) * 2019-01-25 2022-03-24 The Trustees Of The University Of Pennsylvania Compositions and Methods for Targeting Mutant RAS
GB2596461B (en) * 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
EP3760217A1 (en) * 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
CU20220044A7 (es) * 2020-02-12 2023-06-13 Us Health Receptor de células t restringido por hla de la clase i contra ras con mutación g12d
CA3167382A1 (en) * 2020-02-14 2021-08-19 Steven A. Rosenberg Hla class i-restricted t cell receptors against ras with g12v mutation
WO2021173902A1 (en) * 2020-02-26 2021-09-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation
KR20230084524A (ko) * 2020-10-02 2023-06-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G13d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 dq t 세포 수용체
KR102488353B1 (ko) * 2020-10-08 2023-01-12 부산대학교 산학협력단 돌연변이 kras를 표적하는 펩타이드 및 이의 용도
CA3209732A1 (en) 2021-02-25 2022-09-01 Drew Caldwell DENIGER Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022251283A1 (en) * 2021-05-25 2022-12-01 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
WO2023139257A1 (en) 2022-01-21 2023-07-27 T-Knife Gmbh Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
WO2023241522A1 (zh) * 2022-06-14 2023-12-21 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
CN117430689A (zh) * 2022-11-04 2024-01-23 新景智源生物科技(苏州)有限公司 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US9345748B2 (en) * 2010-09-21 2016-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-SSX-2 T cell receptors and related materials and methods of use
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CA2968399A1 (en) 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors
CN108350059B (zh) 2015-09-15 2021-10-08 美国卫生和人力服务部 识别hla-cw8限制性突变kras的t细胞受体
JP6697562B2 (ja) * 2015-12-23 2020-05-20 メディジーン イミュノテラピーズ ゲーエムベーハー 樹状細胞組成物
US11026969B2 (en) * 2015-12-23 2021-06-08 Fred Hutchinson Cancer Research Center High affinity T cell receptors and uses thereof
WO2019112932A1 (en) * 2017-12-04 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells

Also Published As

Publication number Publication date
SG11202005236QA (en) 2020-07-29
JP2021505136A (ja) 2021-02-18
US20230026180A1 (en) 2023-01-26
KR20200115484A (ko) 2020-10-07
EA202091335A1 (ru) 2020-10-15
US20210079058A1 (en) 2021-03-18
JP2023175703A (ja) 2023-12-12
CR20200287A (es) 2020-11-11
CN111836638A (zh) 2020-10-27
MA51042A (fr) 2020-10-14
MA51043A (fr) 2020-10-14
WO2019112941A1 (en) 2019-06-13
CA3084246A1 (en) 2019-06-13
BR112020011111A2 (pt) 2020-11-17
IL275031A (en) 2020-07-30
US11466071B2 (en) 2022-10-11
AU2018378200A1 (en) 2020-07-02
EP3720478A1 (en) 2020-10-14
JP7385566B2 (ja) 2023-11-22

Similar Documents

Publication Publication Date Title
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
AU2021203746B2 (en) T cell receptors recognizing MHC class II-restricted MAGE-A3
MX2020003117A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
SA518391109B1 (ar) Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
CR20200170A (es) Receptores de células t que reconocen p53 mutado
MX2017006865A (es) Receptores de células t de kras anti-mutado.
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
MX2022010157A (es) Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
MX2022009825A (es) Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
BR112017019140A2 (pt) métodos de tratamento de câncer usando células t ativadas
MX2022009654A (es) Receptor de células t restringido por hla de la clase i contra ras con mutación g12d.
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
BR112016023688A2 (pt) célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada
BR112012018457A2 (pt) peptídeos melk modificados e vacinas contendo os mesmos
BR112013013158B1 (pt) composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
WO2021262829A3 (en) Hla class i-restricted t cell receptors against cd20
BR112014024230A8 (pt) Polipeptídeo, derivado do polipeptídeo, ácido nucleico, vetor, célula hospedeira, método de produção do polipeptídeo, composição farmacêutica, kit, método de inibição de atividade de notch, método de tratamento de uma doença, anticorpo isolado, método de o aumento da atividade de notch
MX2017005644A (es) Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.
WO2022015694A8 (en) Hla class ii–restricted drb t cell receptors against ras with g12d mutation
WO2022051449A3 (en) T cell receptors recognizing r273c or y220c mutations in p53
AR104231A1 (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer